Patriot Scientific

Patriot Scientific Reports Profitable Quarter; Q3 FY '08 Net Income $6.3 Million or $0.02 Basic and Diluted Earnings Per Share.
in response to Mark4321's message

Again, it appears you miss the point of Deb's quoted material, and the counter-argument re: Quanta v. LG that I've offerred consistently in Agora posts and in pms to you:

"The Court's ruling underscores the continued viability of the longstanding doctrine of patent exhaustion (also known as the "first sale doctrine"), as well as the importance of using only carefully drafted contracts in connection with the transfer and use of patented products."

My understanding (open to correction) is that this "longstanding doctrine of patent exhaustion" has been in place for over 100 years. No crystal ball required, the court merely upheld its long-standing position.

As I suggested previously, I strongly suspect that the implementation of "...carefully drafted contracts in connection with the transfer and use of patented products" probably occurred within weeks if not days after the original establishment of the doctrine by the SC - a hundred years ago. It was no less an "issue" then as it is today. And certainly contract language has been further refined over all these years to assure that, when desired, the exhaustion issue is overcome.

FWIW and JMHO,

SGE

Please login to post a reply
SGE1
City
Santa Ynez, CA
Rank
President
Activity Points
26509
Rating
Your Rating
Date Joined
12/15/2004
Social Links
Private Message
Patriot Scientific
Symbol
PTSC
Exchange
OTCBB
Shares
401,392,948
Industry
Technology & Medical
Website
Create a Post